REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

News

Is Regeneron a Multimillionaire-Maker Stock? [Yahoo! Finance]
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset [Yahoo! Finance]
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy? [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com